全球癌症免疫疗法市场规模、份额、趋势和成长分析报告（2026-2034年）

预计癌症免疫疗法市场将从 2025 年的 1,161.3 亿美元成长到 2034 年的 4,361.8 亿美元，2026 年至 2034 年的复合年增长率为 15.84%。

随着创新治疗方法不断革新癌症治疗，全球癌症免疫疗法市场正经历快速成长。免疫疗法利用人体自身的免疫系统来靶向并摧毁癌细胞，与传统治疗方法相比，有望提高生存率并减少副作用。全球癌症发生率的上升以及人们对先进治疗方法的认知不断提高，是成长要素。

对研发的大量投入正在加速新型治疗方法的问世，例如查核点抑制剂、CAR-T细胞疗法和单株抗体。製药公司正与研究机构合作开发个人化治疗方案。新型免疫疗法的监管核准也促进了其在关键医疗保健市场的扩张。

随着精准医疗和基于生物标记的治疗方法日益普及，未来前景十分光明。技术进步和不断扩大的临床试验有望扩大多种癌症类型的治疗应用范围。医疗保健支出的成长和政府的支持将在未来几年推动全球癌症免疫疗法市场的持续成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球癌症免疫疗法市场：依产品类型划分

• 市场分析、洞察与预测
• 查核点抑制剂
• 单株抗体
• 疫苗
• 细胞疗法
• 免疫调节剂
• 溶瘤病毒

第五章 全球癌症免疫疗法市场：依应用领域划分

• 市场分析、洞察与预测
• 肺癌
• 乳癌
• 黑色素瘤
• 多发性骨髓瘤
• 摄护腺癌
• 卵巢癌
• 子宫颈癌
• 胃癌
• 结肠癌
• 头颈癌
• 其他的

第六章 全球癌症免疫疗法市场：依最终用户划分

• 市场分析、洞察与预测
• 医院
• 肿瘤诊所
• 居家照护
• 其他的

第七章：全球癌症免疫疗法市场：依形式划分

• 市场分析、洞察与预测
• 静脉注射（IV）
• 肌肉内部
• 口服

第八章 全球癌症免疫疗法市场：按分销管道划分

• 市场分析、洞察与预测
• 直接竞标
• 零售销售
• 药局

第九章 全球癌症免疫疗法市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第十章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十一章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Merck & Co. Inc
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Janssen Pharmaceutical
  • AstraZeneca
  • Gilead Sciences Inc
  • Lilly
  • Amgen Inc
  • Novartis AG
  • GSK Plc
  • Pfizer Inc
  • AbbVie Inc
  • Bayer AG
  • BioNTech SE
  • Moderna Inc

The Cancer Immunotherapy Market size is expected to reach USD 436.18 Billion in 2034 from USD 116.13 Billion (2025) growing at a CAGR of 15.84% during 2026-2034.

The Global Cancer Immunotherapy Market is experiencing rapid growth as innovative treatments transform cancer care. Immunotherapy harnesses the body's immune system to target and destroy cancer cells, offering improved survival rates and fewer side effects compared to traditional therapies. Rising cancer prevalence worldwide and increasing awareness about advanced treatment options are key growth drivers for the market.

Significant investments in research and development are accelerating the introduction of novel therapies such as checkpoint inhibitors, CAR-T cell therapies, and monoclonal antibodies. Pharmaceutical companies are collaborating with research institutions to develop personalized treatment approaches. Regulatory approvals for new immunotherapy drugs are also contributing to expanding market availability across major healthcare markets.

Future prospects remain highly promising as precision medicine and biomarker-based therapies gain traction. Technological advancements and expanding clinical trials are expected to broaden treatment applications across multiple cancer types. Growing healthcare expenditure and supportive government initiatives will likely continue driving the global cancer immunotherapy market toward sustained growth in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Type

• Checkpoint Inhibitors
• Monoclonal Antibodies
• Vaccines
• Cell Therapies
• Immunomodulators
• Oncolytic Virus

By Application

• Lung Cancer
• Breast Cancer
• Melanoma
• Multiple Myeloma
• Prostate Cancer
• Ovarian Cancer
• Cervical Cancer
• Stomach Cancer
• Colorectal Cancer
• Head & Neck Cancer
• Others

By End User

• Hospitals
• Oncology Clinics
• Homecare
• Others

By Form

• Intravenous (IV)
• Intramuscular
• Oral

By Distribution Channel

• Direct Tenders
• Retail Sales
• Pharmacies

COMPANIES PROFILED

• Merck Co Inc, F HoffmannLa Roche Ltd, BristolMyers Squibb Company, Janssen Pharmaceutical, AstraZeneca, Gilead Sciences Inc, Lilly, Amgen Inc, Novartis AG, GSK plc, Pfizer Inc, AbbVie Inc, Bayer AG, BioNTech SE, Moderna Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER IMMUNOTHERAPY MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Checkpoint Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Cell Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Immunomodulators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Oncolytic Virus Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER IMMUNOTHERAPY MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Melanoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Multiple Myeloma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Ovarian Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Cervical Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Stomach Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.10. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.11. Head & Neck Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.12. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER IMMUNOTHERAPY MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Oncology Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER IMMUNOTHERAPY MARKET: BY FORM 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Form
• 7.2. Intravenous (IV) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Intramuscular Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CANCER IMMUNOTHERAPY MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Direct Tenders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Retail Sales Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL CANCER IMMUNOTHERAPY MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Product Type
  • 9.2.2 By Application
  • 9.2.3 By End User
  • 9.2.4 By Form
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Product Type
  • 9.3.2 By Application
  • 9.3.3 By End User
  • 9.3.4 By Form
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Product Type
  • 9.4.2 By Application
  • 9.4.3 By End User
  • 9.4.4 By Form
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Product Type
  • 9.5.2 By Application
  • 9.5.3 By End User
  • 9.5.4 By Form
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Product Type
  • 9.6.2 By Application
  • 9.6.3 By End User
  • 9.6.4 By Form
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL CANCER IMMUNOTHERAPY INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Merck & Co. Inc
  • 11.2.2 F. Hoffmann-La Roche Ltd
  • 11.2.3 Bristol-Myers Squibb Company
  • 11.2.4 Janssen Pharmaceutical
  • 11.2.5 AstraZeneca
  • 11.2.6 Gilead Sciences Inc
  • 11.2.7 Lilly
  • 11.2.8 Amgen Inc
  • 11.2.9 Novartis AG
  • 11.2.10 GSK Plc
  • 11.2.11 Pfizer Inc
  • 11.2.12 AbbVie Inc
  • 11.2.13 Bayer AG
  • 11.2.14 BioNTech SE
  • 11.2.15 Moderna Inc